Effect of estimated prostate volume on silodosin-mediated improvements in the signs and symptoms of BPH: does prostate size matter?

Steven A Kaplan, Claus G Roehrborn, Lawrence A Hill, Weining Volinn

Weill College of Medicine Cornell University, New York, NY, USA; University of Texas Southwestern Medical Center, Dallas, TX, USA; Watson Laboratories Inc., Salt Lake City, UT, USA

Objective: The uroselective α-blocker silodosin significantly improved International Prostate Symptom Score (IPSS) in two 12-week, double-blind (DB), placebo-controlled Phase III studies in men aged ≥ 50 years with symptoms of benign prostatic hyperplasia (BPH) and maintained symptom improvement during a 9-month open-label (OL) extension. This post-hoc analysis evaluated the effects of estimated prostate volume (EPV) on silodosin-mediated symptom improvement.

Methods: Patients were stratified by EPV (<30 mL or ≥ 30 mL) calculated from prostate-specific antigen (PSA) concentrations using a published algorithm. Group comparisons were done by analysis of covariance with last observations carried forward.

Results: Of 890 patients with PSA baseline data, 192 had EPV <30 mL and 698 had EPV ≥ 30 mL. During DB treatment, silodosin was associated with significant symptom improvement (adjusted mean difference versus placebo) in men with EPV <30 mL (−2.0; P = 0.038) and those with EPV ≥ 30 mL (−3.0; P < 0.0001). Among patients who received silodosin during DB treatment, changes from baseline in IPSS to the end of OL extension (mean ± standard deviation) were similar for EPV <30 mL (n = 60, −7.0 ± 6.8) and EPV ≥ 30 mL (n = 242, −8.0 ± 7.1; P = 0.416). Also, among patients who received placebo as DB treatment, symptom improvement at the end of OL extension was similar for EPV <30 mL (n = 62, −6.2 ± 8.1) and EPV ≥ 30 mL (n = 275, −6.7 ± 6.1; P = 0.339).

Conclusion: Silodosin effectively relieved BPH-related symptoms for up to 12 months, irrespective of prostate size, including in patients with enlarged prostates.

Keywords: International Prostate Symptom Score, IPSS, benign prostatic hyperplasia

Introduction

Lower urinary tract symptoms (LUTS) and urinary flow impairment are typical consequences of benign prostatic hyperplasia (BPH). α-Blockers (α1-adrenoceptor antagonists) are the treatment of choice for the rapid relief of BPH-associated symptoms.1

The severity of LUTS is believed to be controlled largely by smooth muscle tone in the prostate and bladder neck, which is mediated primarily by α1A-adrenoceptors.2,3 Silodosin is a uroselective α1A-adrenoceptor antagonist for the treatment of the signs and symptoms of BPH. Its pharmacologic profile is characterized by exceptionally high selectivity for α1A-versus α1B-adrenoceptors and consequently high selectivity for prostatic versus vascular tissue.4-8 The low affinity of silodosin for α1n-adrenoceptors is believed to be responsible for the high level of cardiovascular safety of silodosin, including its low potential for causing orthostatic hypotension.8
Combined efficacy results from two 12-week randomized, placebo-controlled, double-blind, Phase III studies have demonstrated that silodosin provides rapid and significant relief from BPH-related symptoms. Moreover, silodosin-mediated symptom improvement was maintained in a 9-month open-label (OL) extension of the two Phase III studies.  

Although α-blockers are known to provide effective relief of BPH-related LUTS, they do not affect prostate size or hyperplastic growth. This post-hoc analysis of data from the two silodosin Phase III studies and the OL extension study seeks to determine the influence of estimated prostate volume (EPV) on the efficacy of silodosin in improving BPH-associated symptoms.

Methods

Patients and treatment

This post-hoc analysis used combined data from two 12-week double-blind, placebo-controlled, Phase III studies (ClinicalTrials.gov identifiers NCT00224107 and NCT00224120) and the OL extension study (NCT00224133) in patients with BPH-related symptoms. Study participants were men aged ≥50 years with International Prostate Symptom Score (IPSS) ≥13, peak urinary flow of 4–15 mL/s, voided volume ≥125 mL, and postvoid residual urine volume <250 mL. Of the 923 study participants in the two studies, 457 received placebo and 466 received silodosin 8 mg/d. Change from baseline in IPSS was the primary endpoint. A total of 661 patients participated in the OL extension.

Assessments and analyses

To assess the effect of EPV on silodosin-mediated symptom improvement, prostate volume (PV) was estimated from prostate-specific antigen (PSA) serum concentrations using the following equation: log PV = a + b log PSA + c (age – 60) + d (age – 60) × log PSA. A patient was assigned retrospectively to one of two subgroups based on whether or not the EPV met the clinical criterion for pathologic prostate enlargement (≥30.00 mL). Serum PSA concentrations were determined by immunometric assay (Siemens Healthcare Diagnostics IMMULITE Series instrument, linear range 0.01–20.00 ng/mL). All group comparisons were performed by analysis of covariance with baseline as the covariate and last observation carried forward (LOCF) to impute missing data. A 5% significance level (α = 0.05) with no adjustment for multiple comparisons was applied for all statistical tests.

Results

Effect of EPV on symptom improvement during double-blind treatment (12 weeks)

A histogram of the distribution of EPV for all patients with PSA data at baseline is shown in Figure 1. Of 890 patients

![Figure 1](https://www.dovepress.com/)

Figure 1: Histogram of estimated prostate volume. Estimated prostate volume mean ± standard deviation (mL) was 38.43 ± 9.98 (range 18.35–76.79); N = 890.
with PSA data at baseline, 192 had EPV < 30 mL, and 698 had EPV ≥ 30 mL. EPV values ranged from 18 to 77 mL, with a median of 37 mL. Of the 111 patients who had an EPV > 50 mL, 29 patients had an EPV > 60 mL. Observed changes in IPSS total score for silodosin versus placebo in patients with EPV < 30 mL and in those with EPV ≥ 30 mL are shown in Figure 2. Silodosin-mediated decreases in IPSS (mean ± standard deviation) from baseline to week 12 (LOCF) tended to be slightly greater in patients with EPV ≥ 30 mL (−6.7 ± 6.7) than in those with EPV < 30 mL.

Figure 2 Observed changes from baseline in IPSS in patients with EPV < 30 mL (A) and in those with EPV ≥ 30 mL (B). Shown are mean values with 95% confidence intervals.

Abbreviations: BL, baseline; EPV, estimated prostate volume; IPSS, International Prostate Symptom Score; LO, last observation.
Effect of EPV on symptom improvement at the end of OL extension (9 months)

Of the 662 patients who participated in the OL extension study, 639 had PSA data; of those, 122 had EPV $< 30$ mL, and 517 had EPV $\geq 30$ mL. Table 2 shows the effect of EPV on changes in IPSS from baseline (of the double-blind studies) to the end of OL extension. All participants of the OL extension received silodosin 8 mg/d; those who received silodosin as double-blind treatment and those who received placebo as double-blind treatment were analyzed separately. In both analysis groups, symptom improvement at the end of OL extension was numerically and statistically similar for patients with EPV $< 30$ mL and those with EPV $\geq 30$ mL (Table 2 and Figure 3).

Discussion

The results of this post-hoc analysis of data from the two silodosin Phase III studies and the OL extension study show that silodosin provides statistically significant and clinically meaningful symptom relief in patients with BPH-related symptoms, irrespective of prostate size. Decreases in IPSS from baseline to week 12 in each silodosin subgroup (defined by EPV) were significantly greater than the IPSS decreases in the corresponding placebo subgroups. Mean change in IPSS in each silodosin subgroup was similar to that previously observed for the entire silodosin-treated population of the double-blind studies ($-6.4$). $^{10}$ Most importantly, over the 9-month period of the OL extension, differences in silodosin-mediated symptom improvement between patients with EPV $< 30$ mL and those with EPV $\geq 30$ mL were small and not statistically significant. Together, these observations suggest that silodosin can be expected to be effective regardless of prostate size, including in patients with enlarged prostates.

The analysis of the OL extension data also indicates that prostate size is not a meaningful predictor of the extent of silodosin-mediated symptom improvement. Overall, the findings of our analyses are consistent with the results of placebo-controlled studies of other $\alpha$-blockers in patients with BPH symptoms that showed a lack of association between efficacy in symptom relief and prostate size.$^{14,15}$

The original silodosin Phase III studies were not designed to evaluate the effect of PV on the efficacy of silodosin. Consequently, this retrospective analysis has some

---

### Table 2 Changes in IPSS in patients with EPV $< 30$ mL and in those with EPV $\geq 30$ mL at the end of OL extension

| EPV < 30 mL | Silodosin as double-blind treatment | Placebo as double-blind treatment |
|-------------|------------------------------------|----------------------------------|
| BL (double-blind study), mean ± SD | 20.8 ± 5.5 | 21.6 ± 5.2 |
| Change from BL to end of OL extension, mean ± SD | −7.0 ± 6.8 | −8.0 ± 7.1 |
| Adjusted mean difference (95% CI) and $P$-value silodosin versus placebo | $-0.8$ (−2.6 to 1.1) | $-0.8$ (−2.6 to 0.9) |

### Table 1 Changes in IPSS in patients with EPV $< 30$ mL and in those with EPV $\geq 30$ mL at the end of double-blind treatment

| EPV < 30 mL | Silodosin | Placebo |
|-------------|-----------|---------|
| BL, mean ± SD | 21.0 ± 5.2 | 22.0 ± 5.2 |
| Change from BL to week 12, mean ± SD | $-5.4 ± 6.4$ | $-3.7 ± 6.8$ |
| Adjusted mean difference (95% CI) and $P$-value silodosin versus placebo | $-2.0$ (−3.8 to −0.1) | $P = 0.038$ |

### Table 3 Changes in IPSS in patients with EPV $< 30$ mL and in those with EPV $\geq 30$ mL at the end of OL extension

| EPV < 30 mL | Silodosin as double-blind treatment | Placebo as double-blind treatment |
|-------------|------------------------------------|----------------------------------|
| BL (double-blind study), mean ± SD | 22.1 ± 4.9 | 21.3 ± 4.8 |
| Change from BL to end of OL extension, mean ± SD | $-6.2 ± 8.1$ | $-6.7 ± 6.1$ |
| Adjusted mean difference (95% CI) and $P$-value silodosin versus placebo | $-0.8$ (−6.7 to 0.2) | $P = 0.339$ |

---

**Note:** Last observation carried forward for week 12.

**Abbreviations:** BL, baseline; CI, confidence interval; EPV, estimated prostate volume; iPss, International Prostate Symptom Score; OL, open-label; SD, standard deviation.
limitations. Because determination of actual PV was not mandated by the protocol, values for PV were estimated from serum PSA and age using a published algorithm. Although data stratification reduced the power of our treatment group comparisons, both EPV subgroups were large enough to demonstrate the significance of the treatment effects of silodosin versus placebo. Therefore, we believe that the lack of significant differences in symptom improvement between EPV groups during the OL extension is a meaningful result, suggesting that prostate size has no major effect on the extent of silodosin-mediated symptom relief.

**Conclusion**

This retrospective analysis of data from two placebo-controlled Phase III studies and the OL extension study of silodosin in patients with BPH-related symptoms provides evidence that silodosin is effective irrespective of PV. Our findings further suggest that PV is not a clinically meaningful predictor of the extent of silodosin-mediated symptom improvement.

**Acknowledgments**

Writing and editorial assistance funded by Watson Pharmaceuticals, Inc, was provided by Roland Tacke, PhD, Marsha Hall, and Colleen Hedge of Scientific Connexions, Newtown, Pennsylvania.

**Disclosure**

SA Kaplan and CG Roehrborn have served on advisory boards for Watson Pharmaceuticals. LA Hill and W Volinn are employees of Watson Laboratories.

**References**

1. Lepor H. Alpha blockers for the treatment of benign prostatic hyperplasia. *Rev Urol*. 2007;9(4):181–190.
2. Schwinn DA, Roehrborn CG. Alpha-1-adrenoceptor subtypes and lower urinary tract symptoms. *Int J Urol*. 2008;15(3):193–199.
3. Marshall I, Burt RP, Chapple CR. Noradrenaline contractions of human prostate mediated by alpha 1A-(alpha 1c-) adrenoceptor subtype. *Br J Pharmacol*. 1995;115(5):781–786.
4. Shibata K, Foglar R, Horie K, et al. KMD-3213, a novel, potent, alpha 1-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. *Mol Pharmacol*. 1995;48(2):250–258.
5. Yamada S, Okura T, Kimura R. In vivo demonstration of alpha(1A)-adrenoceptor subtype selectivity of KMD-3213 in rat tissues. *J Pharmacol Exp Ther*. 2001;296(1):160–167.
6. Moriarity N, Kurooka Y, Nasu K, et al. Distribution of alpha1-adrenoceptor subtype mRNA and identification of subtype responsible for renovascular contraction in human renal artery. *Life Sci*. 2000;66(10):915–926.
7. Yamagishi R, Akiyama K, Nakamura S, et al. Effect of KMD-3213, an alpha 1a-adrenoceptor-selective antagonist, on the contractions of rabbit prostate and rabbit and rat aorta. *Eur J Pharmacol*. 1996;315(1):73–79.
8. Akiyama K, Hora M, Tatamichi S, et al. KMD-3213, a uroselective and long-acting alpha(1a)-adrenoceptor antagonist, tested in a novel rat model. *J Pharmacol Exp Ther*. 1999;291(1):81–91.
9. Lepor H, Hill LA. Silodosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular tolerability. *Pharmacotherapy*. 2010;30(12):1303–1312.
10. Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. *J Urol*. 2009;181(6):2634–2640.
11. Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study. *Urology*. 2009;74(6):1318–1322.
12. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. *Urology*. 1999;53(3):581–589.
13. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. *J Urol*. 1984;132(3):474–479.
14. Lepor H, Williford WD, Barry MJ, Haakenson C, Jones K. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. *J Urol*. 1998;160(4):1358–1367.
15. Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. *BJU Int*. 2003;92(3):257–261.